WASHINGTON DC (January 16, 2020) – “The Association for Accessible Medicines strongly endorses the Senate’s bipartisan passage of the U.S.-Mexico-Canada Agreement. For the first time in a trade agreement, a balance between support for innovation and access to affordable medicines has been reached. This balance will not only allow the growth of U.S. brand, generic and biosimilar pharmaceutical companies, but will also support increased access to competitively priced medicines in the United States. USMCA is a victory for America’s patients and a template for future trade agreements.”
ATTRIBUTE TO: Chip Davis, President and CEO
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.
